Targeting the EGFR signaling pathway in cancer therapy

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

(2011) N. A. Rizvi et al.   CLINICAL CANCER RESEARCH

Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis

(2011) Fausto Petrelli et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling

(2011) Yong Pil Hwang et al.   MOLECULAR NUTRITION & FOOD RESEARCH

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study

(2010) J. R. Kroep et al.   ANNALS OF ONCOLOGY

The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells

(2010) Cecilia Trinks et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

K-ras as a Target for Lung Cancer Therapy

(2010) Alex A. Adjei   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus

(2010) L. Huo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

(2009) K. L. Blackwell et al.   ANNALS OF ONCOLOGY

Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

(2009) Shirish M. Gadgeel et al.   CANCER

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

(2009) Kim-Son H. Nguyen et al.   Clinical Lung Cancer

Advances in Target Therapy for Lung Cancer

(2009) T. Mitsudomi   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking

(2009) I. H. Madshus et al.   JOURNAL OF CELL SCIENCE

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

(2009) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Skin toxicities associated with epidermal growth factor receptor inhibitors

(2009) Tianhong Li et al.   Targeted Oncology

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges

(2009) Doris R. Siwak et al.   Journal of Oncology

MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells

(2008) M P Ponnusamy et al.   BRITISH JOURNAL OF CANCER

MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells

(2008) P. Chaturvedi et al.   CANCER RESEARCH

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer

(2008) Kirstine Roepstorff et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer

(2008) Weiya Xia et al.   MOLECULAR CARCINOGENESIS

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

(2008) J. H. J. M. van Krieken et al.   VIRCHOWS ARCHIV